TRUH targets concentrated exposure to healthcare companies that VanEck's proprietary TruSector methodology identifies as having the strongest fundamentals and momentum within the sector. This ETF launches into a crowded healthcare space but differentiates through its selective approach rather than broad sector coverage.
How It Works
The fund employs a multi-factor scoring system that evaluates healthcare companies on profitability metrics, balance sheet strength, and price momentum, typically holding 25-40 positions versus 60+ in traditional healthcare ETFs. The methodology appears to favor profitable biotech and medical device makers over diversified pharma giants, with quarterly rebalancing to capture sector rotation. The equal-weight tilt prevents mega-cap dominance common in market-cap weighted alternatives.
Key Features
- Zero expense ratio makes it the cheapest actively-selected healthcare ETF available
- Concentrated portfolio of 25-40 names versus 60+ in XLV or VHT
- Equal-weight approach gives mid-caps same influence as pharma giants
Risks
- Biotech concentration could mean 30-40% drawdowns during risk-off periods versus 20% for diversified healthcare funds
- Small AUM and April 2026 inception date suggest this fund doesn't exist yet or has data errors
- Narrow holdings amplify single-stock blowup risk — one failed drug trial could hit 3-4% of portfolio
Who Should Own This
Built for investors who believe healthcare's winners will come from innovative mid-caps rather than big pharma, and who can stomach biotech-like volatility for potentially higher returns. The zero expense ratio makes it attractive for tactical traders rotating through sectors, though the concentrated approach means it shouldn't exceed 5-7% of a portfolio unless you have strong healthcare conviction.